Retatrutide: What It Is, Trial Results, Side Effects and Legal Status

Last reviewed November 16, 2026. Educational information only, not medical advice.

Retatrutide is the weight-loss drug people online call “reta” or “triple G”. It has produced the largest average weight loss of any obesity medicine tested so far, and it is also being sold widely on the black market before it has been approved anywhere. This page covers what retatrutide is, what the trials actually found, the side effects seen in trials and reported online, and where it stands legally.

The short version

Retatrutide is an experimental once-weekly injection from Eli Lilly. In large phase 3 trials, people on the highest dose lost about a quarter of their body weight over 80 weeks. It is not approved by the FDA or any other regulator, it cannot legally be compounded in the US, and products sold as “research use only” retatrutide are not the drug used in the trials. Lilly plans to apply for FDA approval in the first quarter of 2027.

What is retatrutide?

Retatrutide (development code LY3437943) is a lab-made peptide developed by Eli Lilly, the company behind tirzepatide (Mounjaro and Zepbound). It is given as an injection once a week.

Most current weight-loss drugs act on one or two gut hormone receptors. Semaglutide (Ozempic, Wegovy) acts on the GLP-1 receptor. Tirzepatide acts on GLP-1 and GIP. Retatrutide acts on three: GLP-1, GIP and glucagon, which is why it is nicknamed “triple G”. The GLP-1 and GIP effects reduce appetite and slow digestion. The glucagon effect is thought to increase the energy the body uses and help the liver burn fat, which may explain why weight loss in trials has been larger than with the older drugs.

As of November 2026 it is still investigational. That means the only people taking the real product are volunteers in Lilly’s clinical trials.

What the clinical trials show

Unlike many peptides discussed online, retatrutide has a large body of human research: a phase 2 trial published in 2023, followed by a phase 3 program called TRIUMPH involving thousands of participants.

Phase 2 (2023)

The first major trial, published in the New England Journal of Medicine in 2023, enrolled 338 adults with obesity or overweight and a weight-related health condition, but not type 2 diabetes. After 48 weeks, people on the highest dose had lost an average of 24.2% of their body weight, compared with 2.1% on placebo. Weight was still falling when the study ended.

TRIUMPH-1 (phase 3, obesity without diabetes)

TRIUMPH-1 enrolled 2,339 adults with obesity or overweight and no diabetes, and followed them for 80 weeks. The full results were published in the New England Journal of Medicine on September 29, 2026.

You will see two different headline numbers for this trial, and both are correct:

  • 25.0% average weight loss on the highest dose. This is the figure in the published paper, and it counts everyone who started the trial, including people who stopped the drug.
  • 28.3% average weight loss on the highest dose. This is the figure Lilly led with in its announcement, and it estimates the result for people who stayed on treatment as planned.

The first number is the more realistic one for an average person. In a pre-planned two-year extension for participants with a BMI of 35 or more, Lilly reported average weight loss of about 30%.

TRIUMPH-2 and TRIUMPH-3 (diabetes and heart disease)

TRIUMPH-2 tested retatrutide in adults with obesity or overweight and type 2 diabetes. In the paper published in The Lancet in September 2026, the highest dose produced average weight loss of 18.8% at 80 weeks, compared with 5.1% on placebo. People with diabetes usually lose less weight on these drugs than people without it.

TRIUMPH-3 enrolled 1,949 adults with severe obesity and established heart disease. Lilly reported average weight loss of up to 22.6% at 80 weeks on the highest dose, against 3.2% on placebo, along with lower triglycerides, cholesterol, blood pressure and inflammation markers. The trial was not designed to show whether retatrutide reduces heart attacks or strokes, and the numbers of those events were too small to draw a conclusion either way. A separate long-term cardiovascular outcomes trial is still running.

Lilly says five phase 3 trials have now met their main goals, and that it has enough data to apply for approval for obesity, knee osteoarthritis pain and obstructive sleep apnea.

Doses studied in trials

The phase 3 trials tested target doses of 4 mg, 9 mg and 12 mg, injected once a week. Participants did not start on these doses. They began on a low dose and moved up in steps over several months under medical supervision, because starting high causes much more nausea and vomiting.

These are the doses Lilly is studying, not a recommendation. There is no approved dose of retatrutide, and the trial doses refer to Lilly’s own manufactured product. A vial bought online labeled with a milligram amount may contain more, less, or something else entirely (see the black-market section below). PeptDiary does not provide dosing advice.

Side effects in clinical trials

Side effects in the trials were similar to those of other GLP-1 drugs, mostly affecting the gut, plus a few that appear more specific to retatrutide.

Digestive side effects

In TRIUMPH-1, the most common side effects on the highest dose were nausea (about 42% of participants), diarrhea (about 32%), constipation (about 26%) and vomiting (about 25%). They were mostly mild to moderate and were most common while the dose was being increased.

Dysesthesia (skin sensations)

Retatrutide has a side effect not usually seen with semaglutide or tirzepatide: dysesthesia, an abnormal skin sensation such as tingling, burning, numbness or skin that feels sore to the touch. In TRIUMPH-1 it was reported by 12.5% of people on the highest dose, compared with 0.9% on placebo. It was generally mild to moderate and mostly went away during treatment. Rates were higher in the knee osteoarthritis trial (TRIUMPH-4). Researchers do not yet know why it happens.

Heart rate

Retatrutide raises resting heart rate, as GLP-1 drugs do, and the effect increases with dose. In the phase 2 trial the increase peaked at around 24 weeks and then declined. This is one of the reasons the drug is being studied in a dedicated cardiovascular trial.

Other effects and stopping treatment

Around one in ten people on the higher doses in TRIUMPH-1 reported urinary tract infections, mostly mild. Up to 11.3% of people on the highest dose in TRIUMPH-1 stopped treatment because of side effects. In TRIUMPH-3, which enrolled people with heart disease, the figure was 13.5% on the highest dose, compared with 4.8% on placebo.

When to get help now

Call 911 (or 000 in Australia) for chest pain, fainting, trouble breathing, or swelling of the face or throat. Get urgent medical care for severe stomach pain that does not go away (especially if it spreads to your back), vomiting so bad you cannot keep fluids down, a racing heartbeat that will not settle, or yellow skin or eyes, dark urine and unusual tiredness. Tell the doctor exactly what you took and where it came from.

What people report online, and why it differs

Reddit has several busy communities where people describe taking retatrutide bought online. Looking through posts from May to November 2026, the same questions come up again and again:

  • “Why am I still hungry?” and “Why has my weight stalled?” These are among the most common posts.
  • Heart rate. People report a higher resting pulse, a pounding heartbeat, or an unusually high heart rate when exercising.
  • Nausea and bowel changes, the same gut effects seen in trials.
  • Skin sensitivity: burning, tingling or sore skin, matching the dysesthesia seen in trials.
  • Anxiety, poor sleep and low mood, including some people describing feeling emotionally flat.
  • “Is my new vial different?” People often report feeling very different after switching vials or sellers.
  • Switching from or combining with tirzepatide.

A study published in JAMA Network Open in October 2026 looked at this more systematically. Researchers at the University of Pennsylvania used AI to analyze nearly 150,000 Reddit posts and comments about retatrutide written up to the end of 2025. Excluding expected effects such as weight loss, the most commonly reported symptom was increased appetite, the opposite of what the drug should do. Compared with earlier Reddit posts about semaglutide and tirzepatide, retatrutide posts mentioned sleep problems, energy changes, muscle symptoms and heart rate more often, and nausea less often.

The researchers were clear about the limits. Self-reports cannot prove the drug caused a symptom, and because retatrutide is not legally available, there is no way to know whether people were actually taking genuine retatrutide. One likely explanation for the gap between the trials and Reddit is that many online products contain less of the drug than labeled, a different drug, or contaminants.

Risks of black-market retatrutide

Because retatrutide is not approved, everything sold to the public is unauthorized: outside Lilly’s clinical trials there is no legitimate source. The risks of these products are no longer theoretical:

  • Liver injury in Australia. On June 19, 2026, Victoria’s Chief Health Officer issued a health alert after six cases of acute liver injury since January in people who had used unapproved products labeled retatrutide (including “Reta” and “R-10” or “R-20”). The alert said the damage was possibly caused by a contaminant, and that all such products are at risk.
  • Reported deaths in the US. CBS News reported in October 2026 that the FDA had received at least two reports of deaths in 2026 involving products sold as retatrutide. These came from the FDA’s adverse event reporting system, and the reports alone do not prove the product caused either death. The FDA did not say whether it had verified them.
  • Hospitalizations. The consumer group Public Citizen counted at least 14 hospitalizations reported to the FDA in connection with retatrutide as of June 2026.

A certificate of analysis from a seller does not settle the question. Even a genuine test of one batch does not show that the vial you receive is the same, is sterile, or was stored correctly. Injectable products also carry a risk of infection that pills do not.

It is not FDA approved

Retatrutide has not been approved by the FDA or by any regulator in any country. Lilly has said it plans to submit an application to the FDA in the first quarter of 2027. Submitting an application is not approval: the FDA review usually takes many months after that, so the drug is unlikely to be available on prescription before late 2027 at the earliest, and the outcome is not guaranteed.

It cannot be compounded

The FDA states that retatrutide cannot be used in compounding under federal law. Compounding pharmacies can only use ingredients that meet specific legal criteria, and retatrutide meets none of them. This is different from semaglutide and tirzepatide, which were compounded legally for a time during drug shortages. Any pharmacy, clinic or med spa offering “compounded retatrutide” is not doing so legally.

Retatrutide is also not covered by the October 30, 2026 HHS policy that allows licensed pharmacies to compound six peptides (BPC-157, epitalon, KPV, MOTS-c, Semax and TB-500) while the FDA finishes its review. If you have read that “peptides are now legal”, that policy does not apply here.

“Research use only” is not a loophole

Most online retatrutide is sold with a “research use only” or “not for human consumption” label. The FDA has warned companies that sold retatrutide this way while clearly marketing it for human use, and in August 2026 it sent warning letters to five online peptide sellers that relied on that disclaimer. The same month, Lilly filed six federal lawsuits against four research-chemical sellers, a med spa and a compounding pharmacy. Lilly says it has referred more than 200 sellers to regulators and law enforcement, and has flagged more than 14,000 listings online.

These actions target sellers. We are not lawyers, and the legal position of individual buyers can depend on where you live and how the product is imported. The practical point is that there is no legal retail channel for retatrutide, so there is no legal seller whose product you can trust.

Drug or biologic?

Lilly and the FDA have been in a legal dispute since 2024 over whether retatrutide should be classified as a biologic (a protein-like product) or a conventional drug. The FDA says it falls just short of the size that defines a protein. The outcome affects how Lilly files its application and how long it has before competitors can copy the drug. It does not change the fact that retatrutide is not approved.

Other countries and sport

Retatrutide is not approved by Australia’s TGA, and Australian health authorities have warned people not to use unapproved peptide products. Lilly Canada issued a public safety notice about illegal retatrutide sold online in August 2026.

For athletes: Sport Integrity Australia notes that retatrutide is not named on the 2026 World Anti-Doping Agency list. However, WADA’s “non-approved substances” category (S0) bans any substance with no current approval for human use, which includes drugs still in clinical trials, at all times. Athletes in tested sports should treat it as prohibited and check with their anti-doping agency.

Retatrutide vs tirzepatide and semaglutide

Retatrutide has produced larger average weight loss in trials than semaglutide or tirzepatide have in theirs, but those were separate trials with different participants, so the numbers cannot be compared directly. Retatrutide has not been tested head to head against tirzepatide in a published trial. The trials also suggest a trade-off: more people stopped treatment because of side effects, and dysesthesia is a side effect the older drugs do not usually cause.

Two practical points come up constantly online. First, there is no validated way to convert a tirzepatide or semaglutide dose into a retatrutide dose. Second, no trial has tested retatrutide combined with another GLP-1 drug, so there is no evidence that combining them is safe or adds anything. Anyone currently prescribed semaglutide or tirzepatide should make changes only with their prescriber.

Frequently asked questions

Is retatrutide FDA approved?

No. Retatrutide is an investigational drug and has not been approved by the FDA or any other regulator. Lilly plans to apply for FDA approval in the first quarter of 2027.

When will retatrutide be available?

Not before Lilly’s application is reviewed. Lilly plans to submit it in early 2027, and FDA review usually takes many months, so prescription availability is unlikely before late 2027 at the earliest, and approval is not guaranteed.

Can a compounding pharmacy make retatrutide?

No. The FDA says retatrutide cannot be used in compounding under federal law, and it is not one of the six peptides covered by the October 2026 HHS enforcement policy.

Is “research use only” retatrutide legal?

Selling it for human use is not legal. The FDA has sent warning letters to sellers using “research use only” labels, and Lilly has sued several of them. These products are not the drug used in clinical trials and have no quality oversight.

How much weight do people lose on retatrutide?

In the TRIUMPH-1 trial, people without diabetes on the highest dose lost an average of 25% of their body weight over 80 weeks, counting everyone who started the trial. People with type 2 diabetes lost less, about 19% on the highest dose.

Is retatrutide better than tirzepatide?

Average weight loss in retatrutide trials has been higher than in tirzepatide trials, but the two have not been compared directly in a published trial, and retatrutide had higher rates of stopping treatment because of side effects.

Does retatrutide raise your heart rate?

Yes. Trials found a dose-related increase in resting heart rate that peaked around 24 weeks and then declined. A racing heartbeat that does not settle, chest pain or fainting needs urgent medical care.

What is the tingling or burning skin people mention?

It is called dysesthesia. It was reported by about 12.5% of people on the highest dose in TRIUMPH-1, compared with under 1% on placebo, and was mostly mild and temporary.

Why do people online say retatrutide makes them hungry?

A 2026 study of Reddit posts found increased appetite was the most common symptom reported by people taking unapproved retatrutide, which does not match the trials. Researchers could not confirm what those people were actually taking.

Is retatrutide banned in sport?

It is not named on the 2026 WADA list, but WADA bans substances that are not approved for human use, including drugs still in clinical trials. Athletes should treat it as prohibited and check with their anti-doping agency.

Related: BPC-157: what it is, what the research shows, side effects and legal status

Sources

Similar Posts